Spyre Therapeutics, Inc.
SYRE
$14.67
$0.543.82%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 45.59% | -2.76% | -12.10% | 42.85% | 66.64% |
Total Receivables | -- | -- | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 4.54% | -47.11% | 270.10% | 16.93% | 2.93% |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 44.50% | -3.36% | -10.58% | 42.67% | 65.83% |
|
|||||
Total Current Assets | 44.50% | -3.36% | -10.58% | 42.67% | 65.83% |
Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 0.00% | -96.98% | 0.61% | -0.60% | -74.85% |
Total Assets | 44.50% | -3.43% | -10.57% | 42.63% | 64.94% |
|
|||||
Total Accounts Payable | -87.11% | 59.86% | 4.02% | 246.65% | -46.60% |
Total Accrued Expenses | 86.38% | 56.17% | -74.72% | 27.11% | 88.16% |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Liabilities | -30.85% | 296.73% | 267.10% | 37.91% | -93.21% |
Total Other Current Liabilities | -30.85% | 296.73% | 267.10% | 37.91% | -93.21% |
Total Current Liabilities | -6.05% | 160.10% | -48.33% | 33.90% | -28.74% |
|
|||||
Total Current Liabilities | -6.05% | 160.10% | -48.33% | 33.90% | -28.74% |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 1.27% | -8.59% | -86.48% | 132.40% | 508.34% |
Total Liabilities | -3.22% | 51.91% | -81.61% | 112.45% | 140.75% |
|
|||||
Common Stock & APIC | 22.83% | 1.88% | 37.40% | 1.67% | 67.38% |
Retained Earnings | -6.14% | -8.15% | -4.80% | -5.74% | -9.01% |
Treasury Stock & Other | -87.65% | 363.47% | -52.34% | -220.20% | 328.79% |
Total Common Equity | 110.98% | -21.50% | 769.25% | -3,484.85% | 99.63% |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | 0.00% | 0.00% | -15.74% | 0.00% | -52.23% |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | 0.00% | 0.00% | -15.74% | 0.00% | -52.23% |
|
|||||
Total Common Equity | 110.98% | -21.50% | 769.25% | -3,484.85% | 99.63% |
Total Preferred Equity | 0.00% | 0.00% | -15.74% | 0.00% | -52.23% |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 58.16% | -12.55% | 145.87% | -17.25% | 29.86% |
|